Evommune Inc., a biotechnology company targeting chronic inflammatory diseases, raised $150 million in an initial public offering, adding to the list of companies that have been able to proceed with listings despite the US government shutdown.
The EQT AB-backed company sold 9.38 million shares at $16 each, according to a statement Wednesday. Palo Alto, California-based Evommune had marketed the shares for $15 to $17 each, according to its filings with the US Securities and Exchange Commission.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.